CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to XMT-1660.…
Thu, 15 May 2025 07:20:00 GMT ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate doses Encouraging preliminary time-to-event data in triple-negative breast cancer ...
Thu, 09 Jan 2025 22:00:00 GMT - Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile - Promising clinical activity observed in patients with triple-negative breast ...
Fri, 05 Jan 2024 05:02:00 GMT Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical ...
Tue, 31 Oct 2023 06:00:00 GMT CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Tue, 05 Sep 2023 21:00:00 GMT CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
